TY - JOUR
T1 - Nachweis der BRAF-V600E-Mutation beim metastasierten kolorektalen Karzinom
T2 - Ein QuIP-Ringversuch
AU - Jöhrens, Korinna
AU - Fischer, Josephine
AU - Möbs, Markus
AU - Junker, Klaus
AU - Kirfel, Jutta
AU - Perner, Sven
AU - Laßmann, Silke
AU - Werner, Martin
AU - Borgmann, Vanessa
AU - Bläker, Hendrik
AU - Hummel, Michael
N1 - Funding Information:
Wir danken allen Teilnehmern des Ringversuchs, die diese Studie erm?glicht haben. Insbesondere danken wir Constanze Cieluch f?r die technische Umsetzung des Ringversuchs. Die Durchf?hrung des Ringversuchs wurde von der Pierre Fabre Pharma GmbH unterst?tzt.
Publisher Copyright:
© 2021, The Author(s).
PY - 2022/3
Y1 - 2022/3
N2 - Round robin testing is an important instrument for quality assurance. Increasingly, this also applies to the results of molecular diagnostics in pathology, which directly influence therapy decisions in precision oncology. In metastatic colorectal carcinoma (mCRC), the focus has been on detecting KRAS and NRAS mutations, whose absence allows therapy with EGFR blocking antibodies. Recently, BRAF has been added as another predictive marker, since mCRC patients with BRAF V600E mutation benefit significantly from treatment with encorafenib (a BRAF inhibitor) in combination with cetuximab (anti-EGFR antibody) after systemic therapy. Due to the approval of this treatment in 2020, it is a pre-requisite that BRAF V600E mutation detection in diagnostic pathologies is reliably performed. Therefore, this round robin test with BRAF V600E testing either by immunohistochemistry or molecular methods was performed. The round robin test results demonstrate that molecular BRAF V600E detection is currently clearly superior to immunohistochemical detection.
AB - Round robin testing is an important instrument for quality assurance. Increasingly, this also applies to the results of molecular diagnostics in pathology, which directly influence therapy decisions in precision oncology. In metastatic colorectal carcinoma (mCRC), the focus has been on detecting KRAS and NRAS mutations, whose absence allows therapy with EGFR blocking antibodies. Recently, BRAF has been added as another predictive marker, since mCRC patients with BRAF V600E mutation benefit significantly from treatment with encorafenib (a BRAF inhibitor) in combination with cetuximab (anti-EGFR antibody) after systemic therapy. Due to the approval of this treatment in 2020, it is a pre-requisite that BRAF V600E mutation detection in diagnostic pathologies is reliably performed. Therefore, this round robin test with BRAF V600E testing either by immunohistochemistry or molecular methods was performed. The round robin test results demonstrate that molecular BRAF V600E detection is currently clearly superior to immunohistochemical detection.
UR - http://www.scopus.com/inward/record.url?scp=85119663561&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/010875ba-0173-3583-a4bd-c0872c129f48/
U2 - 10.1007/s00292-021-01022-8
DO - 10.1007/s00292-021-01022-8
M3 - Übersichtsarbeiten
C2 - 34807276
AN - SCOPUS:85119663561
SN - 0172-8113
VL - 43
SP - 126
EP - 134
JO - Pathologe
JF - Pathologe
IS - 2
ER -
